Skip to main content English

Detail

Johannes Thaler
Ap. Prof. Priv.-Doz. Dr. Johannes Thaler, PhD

Department of Medicine I (Division of Hematology and Hemostaseology)
Position: Associate Professor

ORCID: orcid.org/0000-0002-9613-8658
T +43 1 0140 400 27570
johannes.thaler@meduniwien.ac.at

Keywords

Bleeding Time; Blood Coagulation Factors; Body Fluids; Cancer-associated thrombosis ; Hemophilia A; Hemophilia B

Research group(s)

  • Thrombosis and Haemostasis Research Group
    Head: Cihan Ay
    Research Area: Our research focuses on thrombosis and haemostasis, with a particular interest in improving the understanding of risk, clinical course and mechanisms of venous thrombosis and bleeding disorders such as haemophilia. The Thrombosis & Haemostasis Research Group is part of the Department of Medicine I, Clinical Division of Haemotology and Haemostaseology, and jointly affiliated with Comprehensive Cancer Center, Cardiovascular Cluster and the Comprehensive Center for Cardiovascular Medicine.
    Members:

Research interests

My main scientific focus is on the investigation of coagulant extracellular vesicles, tissue factor, and activated factor VII in clinical samples. Another focus is on coagulation assay development and the investigation of potential biomarkers for the prediction of venous thromboembolism in cancer patients.

Techniques, methods & infrastructure

My lab is located in the Anna Spiegel Forschungsgebäude of the Medical University of Vienna. We developed and established dedicated assays (such as an in-house factor Xa generation assay for the quantification of extrinsic tenase complexes, a modified thrombin generation assay, modified whole blood and plasma clotting assays) for the quantification of coagulant extracellular vesicles in clinical samples (e.g. amniotic fluid, ascites, blood, plasma, pleural effusions, human milk, saliva, and urine). We apply state of the art methods for the isolation of extracellular vesicles such as size exclusion chromatography and differential high speed centrifugation and use monoclonal antibodies for the specific blockade of coagulation pathways in buffer, normal plasma or different factor deficient plasmas.